Engineer 1 - Process Development, Pilot Scale Operations

ETFs bought $114.9 million of Moderna stock on Wednesday, October 21, ending a one-day net selling streak. Twenty ETFs were buyers and 10 were sellers. CGGO led with 492,604 shares worth $121.1 million, a 1.06% portfolio weight. IBB added $2.0 million and QQQM $1.0 million. The flows followed a $7.5 million net outflow on October 20 and a $26.1 million net inflow on October 19. Over the last five reported days, ETFs were net buyers on three and net sellers on two. Moderna has a market cap of $80.9 billion. Its trailing 12-month revenue was $2.23 billion, down 27.3% over one year, and the shares have returned 587.11% so far this year.

Moderna named a top employer by Science for twelfth consecutive year. By ValueTheMarkets Oct 23, 2026 Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top... CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment. "At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and make an impact," said Stéphane Bancel, Chief Executive Officer of Moderna. "To be recognized by Science for twelve consecutive years is a testament to the thousands of people who have helped build and evolve this company. What continues to unite us is a shared determination to advance mRNA science and translate that work into meaningful advances for patients." In 2026, Moderna received approval for its fourth and fifth products. mCOMBRIAX(R), the Company's mRNA combination vaccine for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 was granted marketing authorization in the European Union in April 2026. mFLUSIVA(R), a new vaccine against seasonal influenza was approved by the U.S. Food and Drug Administration in August 2026. In August 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene, an investigational individualized mRNA cancer therapy, in combination with KEYTRUDA(R) in patients with resected stage IIB-IV melanoma. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the fourth anniversary of the Moderna Charitable Foundation and issued its fifth annual Impacting Human Health Report. "Being a top employer starts with the strength of our people and what we can accomplish together," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "We are building an organization that brings together the expertise of our people with digital capabilities and AI to solve complex problems in new ways and create an even greater impact for patients." For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2026 survey's findings are based on approximately 5,100 completed surveys from readers of Science, and other survey invitees. A vast majority of the survey participants came from North America (71%), Europe (19%), and Asia/Pacific Rim (6%). For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/2026-s-top-employers-ai-i-do About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how Value The Markets treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with Value The Markets on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Moderna Contacts Media: Chris Ridley VP, Global Head of Communications +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected] A sharper way to see the markets in just 5 minutes. Same news, different lens. Value The Markets cut through the noise and hand you the overlooked ideas and the deeper read the crowd misses. Join 38,000+ investors seeing the markets differently. Important notice and disclaimer. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Moderna stock plunges 25% after melanoma vaccine data leak. A melanoma vaccine data leak wiped $24bn off Moderna before its Madrid presentation, despite a statistically strong Phase 3 result. Shares in Moderna, Inc. (MRNA) closed down 25.2% at $183.88 on 22 October 2026, after a melanoma vaccine data leak surfaced hours before a scheduled presentation in Madrid. The selloff wiped out about $24bn in market value, according to Reuters reporting carried by The Globe and Mail, ending a rally that had lifted the stock more than 500% so far in 2026. Leak hit before the Madrid presentation. Partial results from the Phase 3 INTerpath-001 trial briefly appeared on the medical news site Oncology Central before being taken down, according to an investor notice from the Law Offices of Frank R. Cruz. Trading in Moderna shares was briefly halted once the reports spread, The Motley Fool reported. Merck (MRK), Moderna's partner on the vaccine, fell nearly 1% the same day. The full data had been due for the Presidential Symposium at the European Society for Medical Oncology congress in Madrid on 24 October. What the data actually showed. The vaccine, intismeran autogene (mRNA-4157), is given alongside Merck's Keytruda (pembrolizumab) to patients with high-risk melanoma after surgery. In the Phase 3 trial, the combination cut the risk of recurrence or death by 42% versus Keytruda alone, with a hazard ratio of 0.58 and a two-sided p-value below 0.001, Merck said in its official announcement. The combination also cut the risk of distant metastasis or death by 38%, a hazard ratio of 0.62. Two-year recurrence-free survival stood at 82.2% for patients on the combination versus 70.0% on Keytruda alone, Merck disclosed. Those figures are strong by oncology standards. They fall short, though, of the benchmark investors had been using: a Phase 2b readout from December 2023 that showed a 49% reduction in recurrence or death risk, a figure disclosed in Moderna's 2024 annual report. The gap between 49% and 42% looks like the proximate trigger for the selling, rather than any sign the therapy failed. A sell-the-news move, analysts say. Analysts at William Blair and TD Cowen described the reaction as a classic sell-the-news move rather than a verdict on the trial, Reuters reported via The Globe and Mail. Moderna's stock had priced in high expectations: Citigroup analyst Geoff Meacham downgraded the shares a month earlier, calling the pre-leak valuation 'unjustifiable' given an implied need for roughly $13bn a year in oncology revenue, according to Forbes. The move stayed largely contained to Moderna. Merck's shares were barely affected, and 24/7 Wall St. reported that BioNTech (BNTX) dipped about 2% while Pfizer (PFE) edged higher on the same session, pointing to a selloff specific to Moderna's reliance on the vaccine rather than a sector-wide retreat. Positioning data add to that picture. FINRA's daily short-sale ratio for Moderna held in a narrow band of 0.61 to 0.71 across the ten sessions before the leak, showing no build-up in short interest ahead of the news, according to FINRA figures. The wider market backdrop was equally quiet: the 10-year Treasury yield stood at 5.13% on 21 October, barely moved from 5.12% the prior session, according to Federal Reserve data. Losses persist despite oncology hopes. The episode lands as Moderna continues to post losses from its core business. The company reported a net loss of $782m for the second quarter of 2026, according to its quarterly filing with the SEC. Investors had been betting that the melanoma vaccine, alongside other oncology candidates, could eventually offset declining Covid-19 vaccine revenue, which helps explain why a slightly softer-than-hoped readout hit the shares as hard as it did. Attention now turns to Madrid, where Merck and Moderna are due to present the full INTerpath-001 dataset at the ESMO Presidential Symposium on 24 October. Market participants will be watching whether the formal presentation, including any further safety or subgroup detail, changes the reading of a trial that most oncology specialists still regard as a clear success. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.